Sponsored by
This may be the most important paper of the year so far! This is the preliminary results of the clinical trial of Optune combined with Pembrolizumab (Keytruda) along with Temozolomide for adults with newly diagnosed Glioblastoma. The results are impressive. They compared these patients to matched patients from the ED-14 trial - which was the large phase 3 trial of Optune plus Temozolomide for newly diagnosed patients. By adding Keytruda to Optune plus Temozolomide, the median overall survival was 25.2 months, compared to 15.9 months without the Keytruda. This is from the time Optune was started - which was about 3 months from diagnosis - so add 3 months to those numbers to compare to other treatments! That is very impressive and worth trying. All of the components are approved, but Keytruda is not approved for brain tumors so you might have insurance issues. If you have problems, talk to us and we can sometimes help. Our copay assistance program can help pay for Optune and Temozolomide for you but not the Keytruda yet.